FMC 2011

- Welcome to FMC 2011!
- SCIENTIFIC PROGRAM
- Scientific program
- Topics
- INFORMATION
- Organizing & Scientific Committees
- How to get to Stockholm
- Conference venue
- Important dates
- Contact
- Hotels
- Social program
- Swedish Academy of Pharmaceutical Sciences
- REGISTRATION
- Registration fees
- Cancellation rules
- ABSTRACTS & POSTERS
- Instructions
- SPONSORSHIP
- Our sponsors
- Our exhibitors
- Order form

Scientific program

Here you will find the last updated program.
DOWNLOAD program here. Last updated June 16

Preliminary scientific program.


Time	Sunday June 19, 2011
11.30-14.00	Registration
14.00-14.15	Opening Anders Karlén, Jeff Zablocki, Gerhard Ecker
Chair: Anders Karlén
14.15-15.00	Ben Cravatt, The Scripps Research Institute, USA Activity-based proteomics – applications for enzyme and inhibitor discovery
15.00-15.45	Roberto Pellicciari, University of Perugia, Italy Translating Medicinal Chemistry Research into Targeted Therapeutics. Building on Academic Knowledge.
15.45-17.00	POSTER SESSION II with coffee
SESSION 1 GPCR´s Chair: Jeff Zablocki
17.00-17.30	Craig W. Lindsley, Vanderbilt University, USA Development of allosteric modulators of GPCRs and lipases for the treatment of CNS disorders
17.30-18.00	Thomas Högberg, LEO Pharma, Denmark Development of first in class peripherally restricted CB1 receptor antagonists for treatment of obesity and type 2 diabetes
19.15	Reception


Time	Monday June 20, 2011
SESSION 2 Case studies and Emerging targets Chair: Åsa Rosenquist
09.00-09.30	Thomas Olsson, AstraZeneca, Sweden Nuclear hormone receptors – ligand design, predictions and reality
09.30-10.00	Urszula Gabrowska, Medivir, Sweden Design of cathepsin K inhibitors for the treatment of osteoporosis, osteoarthritis and other bone-related diseases
10.00-10.30	Rolf Johansson, AstraZeneca, Sweden Chemokine antagonists in the combat of inflammatory diseases
10.30-11.00	Coffee and Exhibition
SESSION 3 Chemical neuroscience and selected short talks Chair: Bob Devita
11.00-11.30	Andy Stamford, Merck Research Laboratories, USA Discovery of cyclic acylguanidines as orally active BACE1 inhibitors
11.30-12.00	Klaus Bæk Simonsen, Lundbeck, Denmark Approaches to the treatment of schizophrenia
Short talks Chair: Rasmus Prætorius Clausen
12.15-12.25	James Tarr, Vanderbilt University, USA Optimization and characterization of functionally selective agonists of the m1 acetylcholine receptor
12.25-12.35	Ralph Holl, Westfälische Wilhelms-Universität Münster, Germany Irreversible ligands for the first crystallization of an agonist-bound β2 adrenoceptor
12.35-12.45	Fredrik Almqvist, Umeå University, Sweden Pilicides & curlicides –antibacterial agents targeting bacterial virulence
12.45-13.45	Lunch and Exhibition
13.45-15.15	POSTER SESSION II
SESSION 4 Emerging topics Chair: Christian Krog-Jensen
15.15-15.45	Gilles Tamagnan, Institute for Neurodegenerative Disorders, New Haven, Connecticut, USA Application of PET and SPECT radiotracers in drug development
15.45-16.15	Mathias Uhlén, Royal Institute of Technology (KTH), Sweden The Human Protein Atlas
16.15-16.45	Coffee and Exhibition
SESSION 5 Structure based ligand design Chair: Lennart Bunch
16.45-17.15	Stephen W. Fesik, Vanderbilt University, USA Cancer drug discovery using fragment-based methods
17.15-17.45	Antti Poso, University of Eastern Finland, Finland From hydrogen bonds to hydrophobicity: problems and solutions?
19.30	Conference dinner


Time	Tuesday June 21, 2011
SESSION 6 Protein protein interactions Chair: Joel Barrish
09.00-09.45	Jim Wells, University of California at San Francisco (UCSF), USA Toward drugging the undruggable
09.45-10.15	Kristian Strømgaard, University of Copenhagen, Denmark Targeting protein-protein interactions in the brain
10.15-10.45	Coffee and Exhibition
SESSION 7 ADMET profiling Chair: Jan-Erik Nyström
10.45-11.15	Bruce Car, Bristol-Myers Squibb, USA Toxicogenomics in discovery lead selection and investigative toxicology
11.15-11.45	Scott Boyer, AstraZeneca, Sweden Influencing compound design using safety data
11.45-13.00	Lunch and Exhibition
SESSION 8 Cancer and epigenetics Chair: Antti Poso
13.00-13.30	James Bradner, Dana-Farber Cancer Institute, Boston, USA Direct inhibition of bromodomain-containing proteins
13.30-14.00	Thomas Helleday, Stockholm University; Gray Institute for Radiation Oncology & Biology, University of Oxford Targeting cancer stress signatures with DNA repair inhibitors
14.00-14.30	Rasmus Prætorius Clausen, University of Copenhagen, Denmark Development of chemical probes for histone demethylases
14.30-15.00	Coffee and Exhibition
SESSION 9 Closing lectures Chair: Gerhard Ecker
15.00-15.25	Ferran Sanz, IMIM, Universitat Pompeu Fabra, Barcelona, Spain Integrative Knowledge Management and Modelling in Pharmaceutical Research
15.25-16.10	Stefan Laufer, University of Tübingen, Germany Development of Dibenzosuberones as potent and extremely Selective p38 MAPK inhibitors
16.15	Closing of the meeting Anders Karlén, Jeff Zablocki, Gerhard Ecker

Scientific program